Key facts
| Company | SL Follen Company |
|---|---|
| FDA office | Office of Inspections and Investigations |
| Letter date | June 2, 2026 |
| Subject / product | Foreign Supplier Verification Program (FSVP) |
| CFR citations | FDA Warning Letter |
| Response due | 15 working days from receipt (standard FDA warning-letter requirement) |
| Reference / source ID | sl-follen-company-730191-06022026 |
Violations explained
FDA Warning Letter — Violations FDA cited at SL Follen Company
WARNING LETTER SL Follen Company MARCS-CMS 730191 — June 02, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: Via Express Delivery Product: Food & Beverages Recipient: Recipient Name Stuart L. Follen Recipient Title President SL Follen Company 5050 SW Griffith Dr. Suite 101 Beaverton , OR 97005 United States Issuing Office: Office of Inspections and Investigations United States June 2, 2026 WARNING LETTER Re: CMS #730191 Dear Mr. Follen: On April 6, 2026 through April 10, 2026, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of SL Follen Company located at 5050 SW Griffith Dr. Suite 101, Beaverton, OR 97005. This inspection was conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L. The FSVP regulation requires that importers perform certain risk-based activities to verify that human and/or animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https://www.fda.gov/food/food-safety-modernization-act-fsma/fsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals. During the inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the Fresh Pineapple imported from (b)(4) located in (b)(4) . Because of these significant violations, you are not in compliance with section 805 of the FD&C Act. At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We acknowledge receipt of your response dated April 23, 2026 in which you stated you requested your foreign supplier to include the Food Safety Modernization Act Produce Safety Rule Add-on Module Version 1.3 in their third-party audit, and the foreign supplier responded that the Produce Safety Rule module could be added to the next audit. They anticipated the audit with the Produce Safety Rule module to be completed in late 2026. We are unable to evaluate the adequacy of your response because you have not provided any supporting documentation demonstrating your corrective actions. To date, no additional FSVP documents have been received by FDA. Your significant violations of the FSVP regulation are as follows: You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including each of the following foods: Fresh Pineapple imported from (b)(4) located in (b)(4) . During our inspection you provided the following: (b)(4) audit report for (b)(4) for the audit conducted between (b)(4) through (b)(4) (b)(4) audit report for (b)(4) for the audit conducted between (b)(4) through (b)(4) (b)(4) certificate for (b)(4) issued (b)(4) and the corresponding audit report You stated that your foreign supplier is audited under the (b)(4) standard and you obtained documentation of (b)(4) audits and certification from your foreign supplier. However, the records provided are partially in a foreign language with no English translation. It is not clear how these documents would apply to your FSVP program. You also stated that you did not verify the foreign supplier’s compliance with the Produce Safety Rule. You import fresh produce that may be considered “covered produce” as defined in 21 CFR 112.3. If after review of the fresh produce that you import you determine that you are an importer of covered produce, you must have an FSVP that demonstrates that your supplier is producing the food in compliance with processes and procedures that provide at least the same level of public
What happens next
SL Follen Company is expected to respond to FDA in writing, typically within 15 working days of the letter date, describing the specific corrective and preventive actions taken or planned for each violation cited. FDA reviews that response and any follow-up evidence, and can conduct a re-inspection to confirm the corrections were actually made. If FDA judges the response inadequate, or the underlying conditions serious enough, further action can follow, including product seizure, injunction, import alert, or civil penalties; many Warning Letters are resolved through corrective action alone. This page reflects the Warning Letter as issued and will not reflect any subsequent correction unless FDA publishes a follow-up record. FDA issues Warning Letters after an inspection or other review when it believes a firm has significantly violated FDA regulations; the letter itself is a notice, not a final adjudication.
SL Follen Company’s FDA history
Argus HQ has recorded 1 total FDA action tied to SL Follen Company: 1 warning letter, 0 recalls, 0 approval records, and 0 Form 483 inspection citations.
Full letter text
Read the rest of the full text
Frequently asked questions
- What is an FDA Warning Letter?
- An FDA Warning Letter notifies a company that FDA believes it has significantly violated FDA regulations and that prompt corrective action is required. It is issued after an inspection, sample analysis, or other FDA review, and is a notice -- not a final legal determination and not itself a penalty.
- Does this Warning Letter mean SL Follen Company violated the law?
- FDA's letter documents violations it believes it found at SL Follen Company. A Warning Letter is not a final adjudication of guilt; the company has an opportunity to respond and correct the cited issues, and many Warning Letters are resolved without further enforcement once FDA confirms adequate correction.
- What happens after a Warning Letter is issued?
- The firm generally must respond in writing within 15 working days; FDA reviews the response and can escalate to seizure, injunction, or import alert if it judges the response inadequate. Many Warning Letters are resolved through corrective action alone.
- Has SL Follen Company had other FDA enforcement actions?
- This is the only FDA action Argus HQ has on file for SL Follen Company so far. Argus ingests new FDA enforcement records daily.
Get the next warning letter in this therapeutic area before your team hears about it secondhand.
Weekly briefing, free. Upgrade any time for daily or real-time delivery.
Related enforcement actions
Full FDA history for SL Follen Company- Warning letter (recent): Med Shop Inc / www.medshopinc.com — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): ketaminetroches.com — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): Ketdaxandrugs / www.ketdaxandrugs.org — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): Legit Ketamine Suppliers / www.legitketaminesuppliers.com — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): Ketamine Store / www.ketaminestore.org — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): Buy Keta Online / www.buyketaonline.com — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): Ketamine Troche Store / www.ketaminetrochestore.com — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): All Ketamine HCL / www.allketaminehcl.com — Unapproved New Drugs/Misbranded (2026-06-23) →
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). Foreign Supplier Verification Program (FSVP): FDA Warning Letter to SL Follen Company, June 2, 2026. Digital Empire LLC. Retrieved from https://argushq.ai/warning-letter/sl-follen-730191-2026-06-02
"Foreign Supplier Verification Program (FSVP): FDA Warning Letter to SL Follen Company, June 2, 2026." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/warning-letter/sl-follen-730191-2026-06-02.
Argus HQ Research. "Foreign Supplier Verification Program (FSVP): FDA Warning Letter to SL Follen Company, June 2, 2026." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/warning-letter/sl-follen-730191-2026-06-02.
@misc{argushq_argushq_ai_warning_letter_sl_follen_730191_2026_06_02_2026,
title = {Foreign Supplier Verification Program (FSVP): FDA Warning Letter to SL Follen Company, June 2, 2026},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/warning-letter/sl-follen-730191-2026-06-02},
note = {Accessed: July 13, 2026}
}Source: FDA.gov — Warning Letters ↗

